Background: While academic detailing seems to be the most promising intervention to improve prescribing patterns, implementation could be challenging for small community practices. Objective: A pharmacy-led, interactive, and tailored small-group academic detailing in a federally qualified health center is described. The primary objective of the study was to determine if the small-group academic detailing improved the prescribing patterns of the medical providers for select disease states: type 2 diabetes mellitus (T2DM), hyperlipidemia (HLD), and essential hypertension (HTN). Methods: Prescribing patterns in a federally qualified health center were examined in relation to small-group academic detailing sessions from April 2010 to March 2015. The markers for improvement were the increase in utilizing metformin and statins in patients diagnosed with T2DM and HLD, respectively, and the reduction of β-blocker use in patients diagnosed with essential HTN. Changes in prescribing patterns were evaluated using Pearson’s χ2 and Fisher’s exact tests. Results: The average number of active, adult patients with T2DM, HLD, and essential HTN was 839, 1768, and 2547, respectively. Utilization of metformin in T2DM increased from 5.5% at baseline to 37.7%, statin utilization in HLD increased from 77.1% to 86.9%, and β-blocker use in HTN decreased from 17.9% to 13.8% (P < .005). Conclusions: A pharmacy-led, small-group academic detailing program improved and maintained appropriate prescribing patterns in an underserved community practice. This study serves as a successful pilot emphasizing the pharmacist’s role as an educator and a resource to medical providers regarding appropriate medication use.
ParkinLHagbergKWJickH.Comprehensive comparison of drug prescribing in the United States and United Kingdom. Pharmacotherapy. 2011;31:623-629. doi:10.1592/phco.31.7.623
2.
LenfantC.Shattuck lecture—clinical research to clinical practice—lost in translation?N Engl J Med. 2003;349:868-874.
3.
WoolfSH.The meaning of translational research and why it matters. JAMA. 2008;299:211-213. doi:10.1001/jama.2007.26
4.
StaffordRSRadleyDC.The underutilization of cardiac medications of proven benefit, 1990 to 2002. J Am Coll Cardiol. 2003;41:56-61.
5.
VirabhakSShinogleJA.Physicians’ prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana. Am J Manag Care. 2005;11(Spec No):SP14-SP20.
6.
FischerMAChoudhryNKWinkelmayerWC.Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing?Health Aff (Millwood). 2007;26:800-807.
7.
BergesonJGWorleyKLouderAWardMGrahamJ.Retrospective database analysis of the impact of prior authorization for type 2 diabetes medications on health care costs in a Medicare Advantage Prescription Drug Plan population. J Manag Care Pharm. 2013;19:374-384.
8.
GrindrodKAPatelPMartinJE.What interventions should pharmacists employ to impact health practitioners’ prescribing practices?Ann Pharmacother. 2006;40:1546-1557.
9.
OstiniRHegneyDJacksonCet al. Systematic review of interventions to improve prescribing. Ann Pharmacother. 2009;43:502-513. doi:10.1345/aph.1L488
10.
O’BrienMARogersSJamtvedtGet al. Educational outreach visits: effects on professional practice and health care outcomes. Cochrane Database Syst Rev. 2007;(4):CD000409.
11.
DyrkornRGjelstadSEspnesKALindbækM.Peer academic detailing on use of antibiotics in acute respiratory tract infections. A controlled study in an urban Norwegian out-of-hours service. Scand J Prim Health Care. 2016;34:180-185. doi:10.3109/02813432.2016.1163035
12.
MontañoMBernardyNCSherriebK.Cultivating change door to door: educational outreach to improve prescribing practices in rural veterans with posttraumatic stress disorder. Subst Abus. 2017;38:129-134. doi:10.1080/08897077.2017.1303423
13.
RognstadSBrekkeMFetveitADalenIStraandJ.Prescription peer academic detailing to reduce inappropriate prescribing for older patients: a cluster randomised controlled trial. Br J Gen Pract. 2013;63:e554-e562. doi:10.3399/bjgp13X670688
14.
ClyneBSmithSMHughesCMet al. Sustained effectiveness of a multifaceted intervention to reduce potentially inappropriate prescribing in older patients in primary care (OPTI-SCRIPT study). Implement Sci. 2016;11:79. doi:10.1186/s13012-016-0442-2
15.
American Diabetes Association. Standards of medical care in diabetes—2010. Diabetes Care. 2010;33(suppl 1):S11-S61. doi:10.2337/dc10-S011
16.
American Diabetes Association. 8. Pharmacologic approaches to glycemic treatment: Standards of medical care in diabetes—2018. Diabetes Care. 2018;41(suppl 1):S73-S85. doi:10.2337/dc18-S008
17.
StoneNJRobinsonJGLichtensteinAHet al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25suppl 2):S1-S45. doi:10.1161/01.cir.0000437738.63853.7a
18.
National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
19.
MillsEJWuPChongGet al. Efficacy and safety of statin treatment for cardiovascular disease: a network meta-analysis of 170 255 patients from 76 randomized trials. QJM. 2011;104:109-124. doi:10.1093/qjmed/hcq165
20.
ACCORD Study Group; GinsbergHNElamMBet al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362:1563-1574. doi:10.1056/NEJMoa1001282
21.
ChobanianAVBakrisGLBlackHRet al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
22.
DahlöfBDevereuxRBKjeldsenSEet al. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003.
23.
JamesPAOparilSCarterBLet al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311:507-520. doi:10.1001/jama.2013.284427
24.
ONTARGET Investigators; YusufSTeoKKet al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559. doi:10.1056/NEJMoa0801317
25.
FriedLFEmanueleNZhangJHet al; VA NEPHRON-D Investigators. Combined angiotensin inhibition for the treatment of diabetic nephropathy. N Engl J Med. 2013;369:1892-1903. doi:10.1056/NEJMoa1303154
26.
US Food and Drug Administration. FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. https://www.fda.gov/drugs/drugsafety/ucm293101.htm. Published February 28, 2012. Accessed March 29, 2017.
